XBIOTECH INC (XBIT) Stock Analyst Earnings Estimates
NASDAQ:XBIT - Nasdaq - CA98400H1029 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2020 | 2021 | 2022 | 2023 | 2024 | ||
|---|---|---|---|---|---|---|
| Revenue YoY % growth | 44M | 18.39M -58.20% | 4.01M -78.19% | N/A -100.00% | N/A | |
| EBITDA YoY % growth | -16.04M 44.44% | -22.43M -39.84% | -31.88M -42.13% | N/A -12.19% | N/A -12.55% | |
| EBIT YoY % growth | -18.28M 41.47% | -25.08M -37.20% | -34.49M -37.52% | N/A -8.76% | N/A -11.97% | |
| Operating Margin | -41.55% | -136.38% | -860.10% | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | N/A | N/A | N/A |
All data in USD
| EPS Q2Q % growth |
|---|
| Revenue Q2Q % growth |
| EBITDA Q2Q % growth |
| EBIT Q2Q % growth |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q1 2020 Q2Q % growth | 0.00 100.00% | 0.06 | -0.06 | -100.00% |
| Q4 2019 Q2Q % growth | 14.59 | -0.15 | 14.74 | 9,635.95% |
| Q3 2019 Q2Q % growth | -0.15 | -0.15 | 0.00 | 1.96% |
| Q2 2019 Q2Q % growth | -0.16 | -0.15 | -0.01 | -4.58% |
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q4 2022 Q2Q % growth | 300K -93.33% | % | ||
| Q3 2022 Q2Q % growth | 1.68M -62.83% | % | ||
| Q2 2022 Q2Q % growth | 1.53M -66.23% | % | ||
| Q1 2022 Q2Q % growth | 500K -89.69% | % | ||
| Q4 2021 Q2Q % growth | 4.5M -14.61% | % | ||
| Q3 2021 Q2Q % growth | 4.52M -57.16% | % | ||
| Q2 2021 Q2Q % growth | 4.53M -70.77% | % | ||
| Q1 2021 Q2Q % growth | 4.85M -61.75% | % | ||
| Q1 2020 Q2Q % growth | 12.68M | 7.14M | 5.54M | 77.59% |
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A |
| Revenue | N/A | N/A | N/A | N/A |